PCVX Stock Cash Flow Statements

Vaxcyte Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Vaxcyte Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30

cash flows from operating activities:
net income	-166,573,000	-140,718,000	-137,080,000	-103,124,000	-128,703,000	-95,020,000	-180,801,000	-92,664,000	-68,339,000	-60,462,000	-78,050,000	-57,917,000	-48,532,000	-38,986,000	-28,563,000	-26,615,000	-23,679,000	-21,220,000	-20,737,000	-21,018,000
adjustments to reconcile net income to net cash from operating activities:
depreciation and amortization	2,879,000	2,956,000	2,864,000	1,788,000	1,352,000	999,000	888,000	806,000	750,000	712,000	702,000	684,000	609,000	582,000	459,000	510,000	484,000	347,000	332,000	334,000
stock-based compensation expense	36,927,000	30,615,000	24,370,000	21,265,000	21,558,000	17,629,000	13,348,000	13,220,000	12,544,000	9,648,000	7,009,000	6,648,000	5,894,000	4,099,000	3,158,000	2,937,000	2,769,000	1,865,000	1,935,000	1,838,000
amortization of operating lease right-of-use assets	2,110,000	1,918,000	1,921,000	2,703,000	2,126,000	2,092,000	2,060,000
net accretion of discounts on investments	-4,493,000	-4,913,000	-11,676,000	-6,103,000	-9,934,000	-10,991,000
unrealized foreign exchange gain
changes in operating assets and liabilities:
prepaid expenses and other current assets	-6,667,000	-1,499,000	-3,297,000	-566,000	2,994,000	-4,958,000	15,439,000	7,124,000	9,000	-4,702,000	-2,419,000	1,830,000	-1,769,000	2,791,000	8,937,000	-9,936,000	-5,813,000	-557,000	982,000	-776,000
operating lease right-of-use assets	0	-17,575,000	-45,324,000
other assets	-10,477,000	-6,554,000	-4,459,000	-6,925,000	-6,546,000	-8,581,000	-34,370,000	286,000	462,000	615,000	69,000	802,000	241,000	-1,577,000	-509,000	-3,074,000	485,000	-441,000	-108,000	-11,000
operating lease liabilities	-1,364,000	15,999,000	43,151,000	2,378,000	-1,839,000	-1,804,000	15,416,000	-1,400,000	-1,376,000	-1,356,000	-1,840,000	-1,423,000	-1,205,000	5,619,000	-12,781,000	232,000	-202,000	-105,000
accounts payable	9,525,000	-29,163,000	31,309,000	8,311,000	-10,708,000	5,672,000	6,479,000	694,000	2,263,000	1,789,000	3,471,000	-1,354,000	2,712,000	-1,933,000	-18,071,000	1,498,000	1,918,000	2,185,000	18,772,000	8,129,000
accrued compensation	4,546,000	-14,418,000	8,343,000	5,767,000	3,375,000	-7,968,000	4,131,000	2,510,000	2,536,000	699,000	-2,271,000	1,391,000	790,000	-2,185,000	1,379,000	665,000	403,000	723,000	-1,206,000	758,000
accrued contract manufacturing expenses	35,129,000	8,088,000
accrued expenses	2,999,000	-4,393,000	-9,319,000	8,635,000	-30,615,000	-4,354,000	36,806,000	-2,737,000	-812,000	3,038,000	1,694,000	3,919,000	2,295,000	-737,000	-3,817,000	4,927,000	2,379,000	1,142,000	791,000	-576,000
net cash from operating activities	-121,166,000	-166,274,000	-111,401,000	-60,708,000	-121,394,000	-159,124,000	-128,810,000	-57,548,000	-62,742,000	-47,690,000	-65,221,000	-38,548,000	-39,126,000	-27,702,000	-51,093,000	-28,415,000	-28,680,000	-13,205,000	-10,768,000	-13,055,000
capex	-2,229,000	-1,535,000	3,629,000	-4,697,000	-16,221,000	8,041,000	2,823,000	-11,068,000	6,245,000	-5,552,000	-1,178,000	-1,231,000	-1,073,000	-2,256,000	-887,000	-1,923,000	-3,270,000	291,000	-377,000	-29,000
free cash flows	-123,395,000	-167,809,000	-107,772,000	-65,405,000	-137,615,000	-151,083,000	-125,987,000	-68,616,000	-56,497,000	-53,242,000	-66,399,000	-39,779,000	-40,199,000	-29,958,000	-51,980,000	-30,338,000	-31,950,000	-12,914,000	-11,145,000	-13,084,000
cash flows from investing activities:
purchases of property and equipment	-1,811,000	-5,424,000	-4,021,000	-4,947,000	-7,781,000	-5,678,000	-5,254,000	-7,339,000	2,140,000	-5,609,000	-1,147,000	-843,000	-938,000	-2,920,000	-1,382,000	-1,719,000	-2,208,000	-1,246,000	-722,000	-29,000
purchases of manufacturing facility build-out and equipment construction-in-progress	-7,944,000	-21,327,000
purchases of investments	-349,050,000	-314,485,000	-815,215,000	-1,233,140,000	-350,649,000	-687,697,000	-203,610,000	-209,673,000	-432,834,000	-483,779,000	-71,285,000	-17,591,000	-6,897,000	-6,972,000	-41,062,000	-66,748,000	-56,386,000	-172,145,000
maturities of investments	394,476,000	438,488,000	263,547,000	327,700,000	299,670,000	242,318,000	242,957,000	232,920,000	95,839,000	40,160,000	32,500,000	46,140,000	30,500,000	59,551,000	42,500,000	37,000,000
sales of investments	42,071,000	26,065,000	24,527,000	26,501,000											0	12,998,000
net cash provided (used) in investing activities	77,742,000	123,317,000
cash flows from financing activities:
proceeds from issuance of shares through employee equity incentive plans
proceeds from issuance of common stock from at-the-market offerings, net of issuance costs
proceeds from issuance of common stock from follow-on offerings, net of issuance costs				1,423,176,000
taxes paid related to the net share settlement of equity awards	-717,000	-5,290,000
net cash from financing activities	2,518,000	759,000	4,907,000	1,515,037,000	110,368,000	818,196,000	2,735,000	48,550,000	546,966,000	41,562,000	656,633,000	44,017,000	49,878,000	111,019,000	8,754,000	7,599,000	956,000	487,000	555,000	36,000
effect of exchange rate changes on cash and cash equivalents	800,000	1,172,000	1,350,000	-5,576,000	-1,410,000	6,062,000	-7,682,000	1,051,000	-78,000	23,000	796,000	53,000	-485,000	-227,000	-802,000	333,000	311,000	-281,000
net increase in cash, cash equivalents and restricted cash	-40,106,000	-41,026,000	-662,312,000	531,734,000	-92,842,000	214,061,000	-147,683,000	14,333,000	150,582,000	-454,206,000	556,256,000	40,228,000	36,432,000	132,756,000	-43,059,000	-38,952,000	-47,943,000	-186,390,000
cash, cash equivalents and restricted cash, beginning of period	0	389,195,000	0	0	0	398,554,000	0	0	0	835,528,000	0	0	0	69,856,000	0	0	0	386,200,000
cash, cash equivalents and restricted cash, end of period	-40,106,000	348,169,000	-662,312,000	531,734,000	-92,842,000	612,615,000	-147,683,000	14,333,000	150,582,000	381,322,000	556,256,000	40,228,000	36,432,000	202,612,000	-43,059,000	-38,952,000	-47,943,000	199,810,000
reconciliation of cash, cash equivalents and restricted cash:
cash and cash equivalents	-40,106,000	346,850,000
restricted cash	0	1,319,000
cash, cash equivalents and restricted cash	-40,106,000	348,169,000
supplemental disclosure of non-cash investing and financing activities:
purchases of property and equipment recorded in accounts payable and accrued expenses	-418,000	3,889,000	7,650,000	250,000	-8,440,000	13,719,000	8,077,000	-3,729,000	4,105,000	57,000	-31,000	-388,000	-135,000	664,000	495,000	-204,000	-1,062,000	1,537,000	345,000
proceeds from issuance of common stock from at-the-market offering, not yet received
unrealized foreign exchange loss		-6,617,000
proceeds from exercise of common stock options		6,049,000		11,737,000	2,744,000	5,024,000	2,067,000	2,155,000	884,000	502,000	2,532,000	1,757,000	324,000	282,000	1,568,000	491,000	466,000	487,000	181,000	108,000
supplemental disclosure of non-cash investing activities:
non-cash payments for acquired manufacturing rights
net cash from investing activities			-557,168,000	-917,019,000	-80,406,000	-451,073,000	-13,926,000	22,280,000	-333,564,000	-448,101,000	-35,952,000	34,706,000	26,165,000	49,666,000	82,000	-18,469,000	-20,530,000	-173,391,000	-722,000	21,000
proceeds from issuance of common stock and pre-funded warrants from follow-on offerings, net of issuance costs
proceeds from issuance of common stock under at-the-market offering, net of issuance costs
supplemental disclosures of non-cash investing and financing activities:
issuance of common stock for acquired manufacturing rights
unrealized foreign exchange gains
accrued manufacturing expenses				16,240,000	35,546,000	-51,840,000	10,887,000	27,511,000	-586,000	6,689,000	-2,004,000	5,440,000	-2,026,000	2,416,000	-2,593,000	-366,000	-8,138,000	2,525,000	-11,528,000	-1,744,000
purchases related to manufacturing facility and equipment construction-in-progress				-33,133,000
proceeds from issuance of common stock related to at-the-market offerings, net of issuance costs				89,460,000
release of restricted stock units				-9,336,000	-565,000	-3,306,000	-330,000	-2,605,000	-214,000	-727,000	0
proceeds from issuance of common stock under employee stock purchase plan				0			1,021,000	0
manufacturing facility and equipment construction-in-progress						-6,394,000
sale of investments						6,378,000		6,372,000	1,291,000	1,127,000		7,000,000
proceeds from issuance of common stock related to at-the-market offering, net of issuance costs								49,000,000	0	41,787,000				3,115,000
proceeds from issuance of common stock from follow-on offering, net of issuance costs						816,478,000		0				0
loss on disposal of assets																			2,000	16,000
asset impairment charges											0	0	156,000	57,000					0	0
net amortization (accretion) of premium (discounts) on investments
proceeds from sales of property and equipment
proceeds from issuance of common stock under atm sales program, net of issuance costs
supplemental disclosure of cash flow information:
cash paid for interest											0	0			0	0			0	0
stock issued for payment of accounts payable															1,000	0
net amortization (accretion) of premiums (discounts) on investments
loss on disposal of fixed assets												0	0	44,000
proceeds from sale of property and equipment												0	0	7,000					0
amortization of operating right-of-use assets									1,651,000	1,630,000		1,670,000	1,564,000	1,787,000		346,000	384,000	180,000
net amortization of premiums on investments									-11,844,000	-5,990,000	-1,175,000	-238,000	145,000	321,000	496,000	429,000	330,000	151,000
deferred offering costs included in accounts payable and accrued expenses													-22,000	23,000
change in fair value of redeemable convertible preferred stock warrant																			0	0
deferred rent and other long-term liabilities																			-3,000	-5,000
payments of capital lease obligations																			0	0
proceeds from initial public offering, net of issuance costs
proceeds from issuance of redeemable convertible preferred stock, net of issuance costs																			0	0
proceeds from issuance of common stock related to early exercised stock options																			0	0
proceeds from issuance of common stock under the employee stock purchase plan											483,000	0			398,000	0
conversion of convertible preferred stock into common stock																			0	0
proceeds from issuance of common stock related to at-the-market offering, net of commissions and offering expenses												43,121,000
proceeds from issuance of common stock through atm facility not yet received
proceeds from follow-on public offering, net of underwriters' commissions and discounts														107,622,000
change in fair value of redeemable convertible preferred stock tranche liabilities
proceeds from initial public offering, net of underwriters' commissions and discounts																			0	0
payment of issuance costs for initial public offering																			0	-72,000
payments of deferred offering costs
issuance costs for initial public offering included in accounts payable and accrued expenses																				-1,492,000
deferred offering costs included in accrued expenses
expense on issuance of redeemable convertible preferred stock warrant
accrued legal settlement
net increase in cash and cash equivalents																			-10,848,000	-12,998,000
cash and cash equivalents, beginning of period																			0	0
cash and cash equivalents, end of period																			-10,848,000	-12,998,000
purchases of property and equipment recorded in accounts payable

We provide you with 20 years of cash flow statements for Vaxcyte stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Vaxcyte stock. Explore the full financial landscape of Vaxcyte stock with our expertly curated income statements.

The information provided in this report about Vaxcyte stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.